uniQure(QURE) - 2025 Q2 - Quarterly Results

Exhibit 99.1 uniQure Announces Second Quarter 2025 Financial Results and Highlights of Recent Company Progress ~ Achieved alignment with the FDA on the AMT-130 statistical analysis plan and CMC requirements to support a planned BLA submission in the first quarter of 2026; ~ Company expects to present AMT-130 topline three-year data in September 2025 ~ ~ Presented case study from first participant treated with AMT-260 for refractory mesial temporal lobe epilepsy showing 92% seizure reduction with no serious ...